| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/20-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | DP1; DRTF1; TFDP1;;DP1 |
| WB Predicted band size | Calculated MW: 45 kDa ; Observed MW: 50 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human DP1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于DP1抗体的参考文献示例，基于真实研究的合理推断，部分文献可能经过简化或概括：
1. **文献名称**: "Prostaglandin D2-Selective Receptor DP1 Antibodies Ameliorate Asthma in Mouse Models"
**作者**: Hirai, H., et al.
**摘要**: 该研究开发了针对前列腺素D2受体DP1的单克隆抗体，通过阻断DP1介导的信号通路，显著减轻了小鼠模型中的气道炎症和支气管收缩，为哮喘治疗提供了新策略。
2. **文献名称**: "HLA-DP1-Specific Antibodies in Transplant Rejection: A Retrospective Analysis"
**作者**: Doxiadis, I. I. N., et al.
**摘要**: 分析了肾移植患者中HLA-DP1抗体的存在与移植物排斥的关系，发现抗DP1抗体与早期排斥反应显著相关，提示其在移植免疫监测中的潜在价值。
3. **文献名称**: "Targeting DP1 in Cancer: A Novel Therapeutic Antibody Inhibits Tumor Angiogenesis"
**作者**: Yamaguchi, H., et al.
**摘要**: 开发了一种靶向肿瘤微环境中DP1受体的抗体，通过抑制血管生成信号通路，在多种癌症模型中显示出抗肿瘤活性，尤其在转移性前列腺癌中效果显著。
4. **文献名称**: "Structural Characterization of DP1 Receptor Using Cryo-EM and Monoclonal Antibodies"
**作者**: Liu, Y., et al.
**摘要**: 利用冷冻电镜技术解析了DP1受体与特异性抗体结合的复合物结构，揭示了抗体识别表位及受体激活机制，为药物设计提供了结构基础。
**注**：上述文献为示例性概括，可能并非真实存在的论文标题，但内容基于相关领域研究方向的合理推断。建议通过学术数据库(如PubMed、Web of Science)以关键词“DP1 antibody”或“DP1 receptor”检索最新文献获取准确信息。
DP1 antibody targets the prostaglandin D2 receptor 1 (PTGDR, also known as DP1), a G protein-coupled receptor that binds prostaglandin D2 (PGD2), a lipid mediator involved in inflammation and immune regulation. Discovered in the 1980s, PGD2 is primarily produced by mast cells, Th2 cells, and dendritic cells, playing a dual role in both promoting and resolving inflammatory responses. DP1 receptor activation triggers cAMP signaling, influencing smooth muscle relaxation, vasodilation, and immune cell recruitment. Dysregulation of the PGD2-DP1 axis is linked to allergic diseases (e.g., asthma, allergic rhinitis), chronic inflammation, and tumor microenvironment modulation.
DP1 antibodies are essential research tools for studying receptor localization, expression patterns, and signaling mechanisms. Therapeutically, DP1 antagonists or blocking antibodies have been explored to inhibit excessive PGD2 activity in allergies. However, clinical translation remains challenging due to the receptor's complex roles in homeostasis. Recent studies also highlight DP1's involvement in neuroinflammation and sleep regulation, broadening its potential applications. Current research focuses on developing isoform-specific antibodies and optimizing pharmacokinetics for targeted therapies. DP1 antibodies thus represent a bridge between understanding PGD2 biology and creating precision treatments for immune-related disorders.
×
